Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Vicore Pharma Holding ABNASDAQ: VCRE

Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Investing cash flow turns positive

Q2 FY2026 investing cash flow was SEK 199.25M, compared with -SEK 250.29M a year earlier. Trailing-twelve-month investing cash flow was -SEK 103.44M.

Context

  • Investing cash flow amounted to 15732.4% of revenue in FY2025, up 15596.1 pp from a year earlier.
  • Investing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly investing cash flow holds near SEK 199.25M or moves back toward the trailing-twelve-month quarterly average of -SEK 25.86M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
SEK 199.25M+324.7% QoQ
Last fiscal yearDec 2025
-SEK 600.51M-502.9% YoY
LTMJun 2026
-SEK 103.44M-78.5% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+179.6%——
1 year-502.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

SEK · from the cash flow

Latest · FY2025
(600.51M) SEK
Year-over-year change
-502.9%

Investing Cash Flow vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -78.5% is the lowest of 2, against a peer median of +197.2%.
  • Investing cash flow amounts to 7777.6% of revenue for VCRE, versus a peer median of 5.2%.
VCRE Competitors
Investing Cash Flow for VCRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VCREVicore Pharma Holding ABLTM Jun 2026SEK 103.44M SEK-78.5%—7777.6%
LQDALiquidia CorporationLTM Jun 2026$23.52M USD+197.2%+121.0%5.2%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —+197.2%+121.0%5.2%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.78M)(290.73M)(321.51M)(194.19M)(452.39M)
Depreciation & Amortization397.75K3.61M3.42M2.24M0
Deferred Income Tax00000
Stock-Based Compensation(172.79K)0000
Change in Working Capital(37.59K)(20.94M)(10.65M)(1.84M)40.81M
Accounts Receivables(37.59K)(1.6M)(4.28M)(35.6M)(3.08M)
Inventory00000
Accounts Payables00000
Other Working Capital0(19.34M)(6.36M)33.77M43.89M
Other Non-Cash Items(231.23M)8.13M79.15M28.84M35.84M
Operating Cash Flow(263.82M)(299.92M)(249.58M)(164.95M)(375.74M)
Capital Expenditures0(3M)000
Acquisitions (Net)00000
Purchases of Investments(76.61M)0(199.04M)(64.81M)(983.95M)
Sales of Investments69.64M77M54.58M213.85M383.45M
Other Investing Activities00000
Investing Cash Flow(6.96M)74M(144.46M)149.04M(600.51M)
Debt Repayment00000
Common Stock Issued316.8M200M500.41M882.14M455.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(237.78K)(12.96M)(29.55M)(48.08M)(24.55M)
Financing Cash Flow316.56M187.04M470.86M834.06M430.54M
Effect of Forex Changes(26.64M)1.48M04.23M(32.16M)
Net Change in Cash2.3M(37.4M)76.82M822.38M(577.85M)
Free Cash Flow(263.82M)(302.92M)(249.58M)(164.95M)(375.74M)

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.